TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15872350

Group type: EXPERIMENTAL
Intervention: CWU+PET (n = 51)
Number of subjects: 102

Group type: COMPARATOR
Intervention: CWU (n = 51)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 102

Group type: COMPARATOR
Intervention: CT/MRI
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: CWU+PET
Number of subjects: 102
Study: 12664022

Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg, once daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10630824

Group type: EXPERIMENTAL
Intervention: Cefepime administered as an intravenous bolus or as a rapid infusion
Number of subjects: 16
Study: 8657838

Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2355106

Group type: EXPERIMENTAL
Intervention: HP 029 at 450 mg/day (150 mg three times a day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HP 029 at 300 mg/day (100 mg three times a day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HP 029 at 225 mg/day (75 mg three times a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 322539

Group type: EXPERIMENTAL
Intervention: Ketamine with pethidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine at two dose levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30376130

Group type: EXPERIMENTAL
Intervention: ABT-122 (60 mg EOW to 240 mg every week)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg EOW)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo (for PsA patients only)
Number of subjects: 461
Study: 28372678

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal catheter (NPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nasal cannula (NC)
Number of subjects: 60
Study: 26318734

Group type: EXPERIMENTAL
Intervention: Referral templates used by GPs in the intervention group.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (no referral templates used).
Number of subjects: 500
Study: 23764202

Group type: EXPERIMENTAL
Intervention: GnRH agonist withdrawal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-withdrawal of GnRH agonist)
Number of subjects: 0
Study: 22182483

Group type: EXPERIMENTAL
Intervention: Planning Tool (PT)
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Combined Planning Tool and Text Reminders (PTT)
Number of subjects: 858

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 858
Study: 17895917

Group type: EXPERIMENTAL
Intervention: acute tryptophan depletion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: acute tyrosine/phenylalanine depletion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: acute tyrosine/phenylalanine/tryptophan depletion (combined monoamine depletion)
Number of subjects: 16

Group type: COMPARATOR
Intervention: balanced/placebo control
Number of subjects: 16
Study: 17146416

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75-300 mg/day
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Fluoxetine 20-60 mg/day
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 1100
Study: 14633326

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with bicalutamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine with cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan with fluorouracil (and leucovorin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab added to standard chemotherapy in HER2 positive metastatic breast cancer
Number of subjects: 0
Study: 11052243

Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide (N2O) in oxygen (O2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous thiopental followed by mask inhalation with 100% O2 and 1.13% halothane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous thiopental followed by mask inhalation with 2.52% enflurane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous thiopental followed by mask inhalation with 1.73% isoflurane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 70% N2O in oxygen and 0.44% halothane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 70% N2O in oxygen and 0.86% enflurane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 70% N2O in oxygen and 0.75% isoflurane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam and ketamine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam and alfentanil
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 45
Study: 9446042

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler method (TCD) for examining blood flow velocities of middle cerebral arteries (MCAs)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Duplex-scan method for examining blood flow velocities of extracranial parts of internal carotid arteries (ICAs)
Number of subjects: 34
Study: 8405644

Group type: EXPERIMENTAL
Intervention: Pefloxacin/Metronidazole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Doxycycline/Metronidazole
Number of subjects: 40
Study: 3769402

Group type: EXPERIMENTAL
Intervention: Capsaicin injection (0.5 micrograms/kg and 4 micrograms/kg)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Capsaicin injection after inhalation of 5% bupivacaine aerosol
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control solution (not specified)
Number of subjects: 3
Study: 30352556

Group type: EXPERIMENTAL
Intervention: Free baseline HIV self-testing (HIVST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular (every 3 months) free HIVST with testing reminders
Number of subjects: 0

Group type: COMPARATOR
Intervention: No free baseline HIVST
Number of subjects: 0

Group type: COMPARATOR
Intervention: No offer of regular (every 3 months) free HIVST
Number of subjects: 0
Study: 26762986

Group type: COMPARATOR
Intervention: Conventional electrophysiotherapy (ultrasound, laser, and interferential current techniques)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided galvanic electrolysis technique (USGET)
Number of subjects: 60
Study: 24599195

Group type: EXPERIMENTAL
Intervention: Open repair
Number of subjects: 196

Group type: COMPARATOR
Intervention: Arthroscopic repair
Number of subjects: 196
Study: 22607165

Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation Mental Health program (R&R2 MHP)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Waiting-list control (treatment as usual)
Number of subjects: 121
Study: 21036883

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy plus chemoradiotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: PF chemoradiotherapy alone
Number of subjects: 101
Study: 18416793

Group type: EXPERIMENTAL
Intervention: Acupressure and meridian massage (15 minutes per session, 3 times daily for 10 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acupressure and meridian massage
Number of subjects: 40
Study: 15864233

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 12621740

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 199

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 199
Study: 10520799

Group type: EXPERIMENTAL
Intervention: In-hospital presentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Out-of-hospital presentation
Number of subjects: 0
Study: 7497653

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty after failed high tibial osteotomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Total knee arthroplasty after failed unicompartmental knee arthroplasty
Number of subjects: 60
Study: 2349916

Group type: EXPERIMENTAL
Intervention: Oyster diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clam diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Crab diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mussel diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Squid diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Shrimp diet
Number of subjects: 18
Study: 6452793

Group type: EXPERIMENTAL
Intervention: Zimelidine (100 mg b.i.d.)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Maprotiline (75 mg b.i.d.)
Number of subjects: 55
Study: 31220980

Group type: EXPERIMENTAL
Intervention: Greater acculturation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Greater psychological distress
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Greater alcohol problems
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Alcohol use and psychological distress
Number of subjects: 76
Study: 29578373

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) training, 40 hours
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study: 26647412

Group type: EXPERIMENTAL
Intervention: New Medicine Service (NMS)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Normal practice
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: NMS
Number of subjects: 504
Study: 24871247

Group type: EXPERIMENTAL
Intervention: Google
Number of subjects: 48

Group type: COMPARATOR
Intervention: Summary Resource
Number of subjects: 48
Study: 21574826

Group type: EXPERIMENTAL
Intervention: LESS cholecystectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 60
Study: 20669296

Group type: EXPERIMENTAL
Intervention: Melevodopa/carbidopa effervescent tablets (M/C)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Standard oral formulation levodopa/carbidopa tablets (L/C)
Number of subjects: 221
Study: 17326911

Group type: COMPARATOR
Intervention: Pavulon (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Midazolam (group 3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both midazolam and pavulon (group 2)
Number of subjects: 30
Study: 16013016

Group type: COMPARATOR
Intervention: Standard bicarbonate dialysis (unselected filters)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Biocompatible treatments (on-line hemofiltration or HD with ultra-pure dialysate and biocompatible membranes)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Biocompatible treatments
Number of subjects: 51
Study: 12408283

Group type: EXPERIMENTAL
Intervention: Immunomodulator containing Mycobacterium w
Number of subjects: 134

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 134
Study: 9624239

Group type: EXPERIMENTAL
Intervention: low‐dose short‐term chemotherapy (one cycle of doxorubicin, vincristin (AV) and one cycle of cyclophosphamide, methotrexate, fluorouracil (CMF))
Number of subjects: 277

Group type: COMPARATOR
Intervention: no chemotherapy
Number of subjects: 277
Study: 8091320

Group type: EXPERIMENTAL
Intervention: Ventstream nebuliser
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ventstream nebuliser at 5.0 mg dose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hudson nebuliser
Number of subjects: 8
Study: 3415710

Group type: EXPERIMENTAL
Intervention: ISMN‐20 (elantan 20)
Number of subjects: 3624

Group type: EXPERIMENTAL
Intervention: ISMN‐50 (elantan long)
Number of subjects: 3624
Study: 30559838

Group type: EXPERIMENTAL
Intervention: PFOA group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 27546446

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (36 IU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25022724

Group type: EXPERIMENTAL
Intervention: DSS module added to existing computer decision support system
Number of subjects: 360
Study: 22406757

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg of alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19558387

Group type: EXPERIMENTAL
Intervention: Inspiratory flow resistive loading (IFRL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham-IFRL
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 18759645

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) 10, 15, 20, or 30 mg/9 h
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15977122

Group type: EXPERIMENTAL
Intervention: CT-based navigation system (group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: CT-free navigation system (group B)
Number of subjects: 44
Study: 15179662

Group type: EXPERIMENTAL
Intervention: Computerized biofeedback knee goniometer (CBG) with audiovisual feedback
Number of subjects: 25

Group type: COMPARATOR
Intervention: Computerized biofeedback knee goniometer (CBG) with no feedback
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Comparison of CBG readings to manual measurements
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Patient satisfaction assessment
Number of subjects: 25
Study: 10682045

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWH)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 48
Study: 9061172

Group type: EXPERIMENTAL
Intervention: Operative intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Tenotomy (radicality varies)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Open neurolysis
Number of subjects: 75

Group type: COMPARATOR
Intervention: Neurolysis for strictures on proximal side of epicondyle
Number of subjects: 75
Study: 8333815

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 3596050

Group type: EXPERIMENTAL
Intervention: Oral administration of BCG in enteric-coated capsules
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chemotherapy without BCG administration
Number of subjects: 29
Study: 2493409

Group type: EXPERIMENTAL
Intervention: Energy‐Nitrogen Dense diet (1.5 kcal/ml; 9.4 gN/l)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard diet (1.0 kcal/ml; 6.3 gN/l)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Energy Dense diet (1.5 kcal/ml; 7.8 gN/l)
Number of subjects: 118
Study: 27995228

Group type: EXPERIMENTAL
Intervention: 15% Chitosan gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open flap debridement (Control)
Number of subjects: 10
Study: 31675982

Group type: EXPERIMENTAL
Intervention: Low-FiO2 (30% FiO2)
Number of subjects: 252

Group type: COMPARATOR
Intervention: High-FiO2 (80% FiO2)
Number of subjects: 252
Study: 28753012

Group type: EXPERIMENTAL
Intervention: Milk intake
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cheese intake
Number of subjects: 11

Group type: COMPARATOR
Intervention: Soy-based drink (control)
Number of subjects: 11
Study: 26009576

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 308

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 308
Study: 24247193

Group type: EXPERIMENTAL
Intervention: Group 3: four stretching exercises of four repetitions
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Group 2: one stretching exercise of four repetitions
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Group 1: standard 'sit and reach' test of four trials
Number of subjects: 239

Group type: COMPARATOR
Intervention: Group 4: no stretching performed
Number of subjects: 239
Study: 21741057

Group type: EXPERIMENTAL
Intervention: Metreleptin (initial dose, 0.08 mg/[kg·d] for 3 months; altered to 0.12 mg/kg or 0.04 mg/[kg·d])
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metreleptin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19567900

Group type: EXPERIMENTAL
Intervention: Colour Your Life (online, multimedia, interactive CCBT programme)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) by a general practitioner
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Combination of Colour Your Life and TAU
Number of subjects: 303
Study: 16752265

Group type: EXPERIMENTAL
Intervention: Immediate catheter removal (group A)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Catheter removal at 6 hours (group B)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Catheter removal at 12 hours (group C)
Number of subjects: 96
Study: 15133009

Group type: EXPERIMENTAL
Intervention: Heavy-intensity warm-up (6 min)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 11
Study: 11697757

Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 9164692

Group type: EXPERIMENTAL
Intervention: linopirdine (30 mg three times per day)
Number of subjects: 382

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 382
Study: 8127930

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3299395

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily for 2 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily plus Verapamil 160 mg twice daily for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Verapamil 160 mg twice daily for 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 18
Study: 28664750

Group type: EXPERIMENTAL
Intervention: Preemptive Ethanol Lock Therapy (ELT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rescue Ethanol Lock Therapy (ELT)
Number of subjects: 14
Study: 26917477

Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg, twice a week for three months
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Gestrinone double dose first month, then twice a week for two months
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Gestrinone three times a week for three months
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Gestrinone treatment
Number of subjects: 195
Study: 25569481

Group type: EXPERIMENTAL
Intervention: Telemetric blood pressure measurement (TBPM)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard-care control group (C-G)
Number of subjects: 57
Study: 23899190

Group type: EXPERIMENTAL
Intervention: Self-reported sedentary time (questionnaire including six sedentary activities)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Objective sedentary time (measured by Actigraph GT3X accelerometer)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Self-reported sedentary time (using TV watching only)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Test-retest reliability of the sum of six sedentary activities
Number of subjects: 83
Study: 20498392

Group type: EXPERIMENTAL
Intervention: Genetic information regarding cognitive impairment risk (CI) after chemotherapy
Number of subjects: 365
Study: 18374884

Group type: EXPERIMENTAL
Intervention: Clenbuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16926710

Group type: COMPARATOR
Intervention: High-dose alcohol preload
Number of subjects: 8

Group type: COMPARATOR
Intervention: Alcohol preload
Number of subjects: 8

Group type: COMPARATOR
Intervention: No alcohol preload
Number of subjects: 8
Study: 12594146

Group type: EXPERIMENTAL
Intervention: Monitor group (n=57)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Monitor-blind group (n=40)
Number of subjects: 97
Study: 10764439

Group type: EXPERIMENTAL
Intervention: Special-purpose standardized pathology form
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional hospital pathology reports
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Trained review pathologists
Number of subjects: 300
Study: 8777169

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy followed by high-dose split course radiotherapy (CT + RT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: High-dose radiotherapy only (RT only)
Number of subjects: 70
Study: 1725550

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of 120 mg/day diltiazem and 20 mg/day nitrendipine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 6409196

Group type: EXPERIMENTAL
Intervention: L-Deprenil treatment
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30156086

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 20
Study: 29439732

Group type: EXPERIMENTAL
Intervention: Decision training for novice occupational therapists
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control group (no training, just encouragement)
Number of subjects: 289
Study: 26773574

Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCI with bivalirudin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ioxaglate (Hexabrix) and Iodixanol (Visipaque)
Number of subjects: 100
Study: 24176723

Group type: EXPERIMENTAL
Intervention: Intervention package promoting effective neonatal resuscitation training
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 184
Study: 22312088

Group type: EXPERIMENTAL
Intervention: Endovascular treatment of chronic cerebro-spinal venous insufficiency
Number of subjects: 67
Study: 20233428

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 103
Study: 18692615

Group type: EXPERIMENTAL
Intervention: SILCS diaphragm with 2% nonoxynol-9 (N-9) gel
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SILCS diaphragm with lubricant
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SILCS polymer spring diaphragm with 2% nonoxynol-9 (N-9) gel
Number of subjects: 15